Latest On Rexahn Pharmaceuticals, Inc (REXN):
About Rexahn Pharmaceuticals, Inc (REXN):
As of November 5, 2020, Rexahn Pharmaceuticals, Inc. was acquired by Ocuphire Pharma, Inc., in a reverse merger transaction. Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's product pipeline include RX-3117, which is in Phase IIa clinical trials for the treatment of patients with relapsed or refractory metastatic pancreatic cancer, as well as bladder, colon, lung and cervical cancer. It is also developing RX-0301, which is in preclinical development stage for the treatment of hepatocellular carcinoma. Rexahn Pharmaceuticals, Inc. has collaboration agreements with Zhejiang Haichang Biotechnology Co., Ltd.; and BioSense Global LLC. The company is headquartered in Rockville, Maryland.
General
- Name Rexahn Pharmaceuticals, Inc
- Symbol REXN
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 5
- Last Split Factor1:12
- Last Split Date2019-04-12
- Fiscal Year EndDecember
- IPO Date2005-05-23
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Web URLhttp://www.rexahn.com
Valuation
- Price/Sales (Trailing 12 Mt.) 6.41
- Price/Book (Most Recent Quarter) 1.42
- Enterprise Value Revenue 0.12
- Enterprise Value EBITDA 0.02
Financials
- Most Recent Quarter 2020-09-30
- Operating Margin -559%
- Return on Assets -34%
- Revenue 1.15 million
- Earnings Per Share -$4.83
- Revenue Per Share $0.28
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 2.03 million
- EBITDA -16533446
- Analyst Target Price $3
- Book Value Per Share $2.93
Share Statistics
- Shares Outstanding 4.48 million
- Shares Float 4.01 million
- % Held by Insiders 22%
- % Held by Institutions 8.33%
- Shares Short 13595
- Shares Short Prior Month 2963
- Short Ratio 0.05
Technicals
- Beta 0.97
- 52 Week High $8.45
- 52 Week Low $1.26
- 50 Day Moving Average 7.9
- 200 Day Moving Average 9.37
Dividends
- Dividend Date N/A
- ExDividend Date N/A
Rexahn Pharmaceuticals, Inc (REXN) Dividend Calendar:
Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
---|
Rexahn Pharmaceuticals, Inc (REXN) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
---|---|---|---|---|---|
2020-06-30 | 2020-08-10 | $N/A | -$0.62 | ||
2020-03-31 | 2020-05-18 | $N/A | -$0.15 | ||
2019-12-31 | 2020-02-21 | $N/A | -$0.46 | ||
2019-09-30 | 2019-11-06 | $N/A | -$0.49 | -$0.54 | 9.26% |
2019-06-30 | 2019-08-07 | $N/A | -$0.61 | -$0.85 | 28.24% |
2019-03-31 | 2019-05-10 | $N/A | -$0.62 | -$0.93 | 33.33% |
2018-12-31 | 2019-03-07 | $N/A | -$1.08 | -$1.56 | 30.77% |
2018-09-30 | 2018-11-02 | $N/A | -$2.04 | -$2.04 | 0% |
2018-06-30 | 2018-08-03 | $N/A | -$1.44 | -$2.19 | 34.25% |
2018-03-31 | 2018-05-04 | -$0.84 | -$1.68 | 50% | |
2017-12-31 | 2018-03-09 | -$1.08 | -$1.64 | 34.15% | |
2017-09-30 | 2017-11-03 | -$0.48 | -$2.56 | 81.25% | |
2017-06-30 | 2017-08-04 | $0.36 | -$2.52 | 114.29% | |
2017-03-31 | 2017-05-04 | -$10.80 | -$2.00 | -440% | |
2016-12-31 | 2017-02-24 | $0.10 | -$0.25 | 140% | |
2016-09-30 | 2016-11-04 | $N/A | -$0.10 | -$0.20 | 50% |
2016-06-30 | 2016-08-08 | $N/A | -$0.10 | -$0.20 | 50% |
2016-03-31 | 2016-05-09 | $N/A | -$0.20 | -$0.20 | 0% |
2015-12-31 | 2016-03-14 | -$0.20 | -$0.25 | 20% | |
2015-09-30 | 2015-11-02 | $N/A | -$0.20 | -$0.33 | 39.39% |
2015-06-30 | 2015-08-07 | $N/A | -$0.20 | -$0.27 | 25.93% |
2015-03-31 | 2015-05-08 | $N/A | -$0.02 | -$0.03 | 33.33% |
2014-12-31 | 2015-03-17 | -$0.02 | -$0.02 | 0% | |
2014-09-30 | 2014-11-12 | $N/A | -$0.01 | -$0.02 | 50% |
2014-06-30 | 2014-08-13 | $N/A | $0.13 | -$2.40 | 105.47% |
2014-03-31 | 2014-05-14 | $N/A | -$10.80 | -$2.40 | -350% |
2013-12-31 | 2014-03-21 | -$1.20 | -$3.60 | 66.67% | |
2013-09-30 | 2013-11-14 | -$2.40 | -$1.80 | -33.33% | |
2013-06-30 | 2013-08-28 | -$3.12 | |||
2013-03-31 | 2013-05-09 | -$1.20 | -$2.40 | 50% | |
2012-12-31 | 2013-03-22 | -$0.06 | -$2.40 | 97.68% | |
2012-09-30 | 2012-11-28 | -$3.76 | |||
2012-06-30 | 2012-08-29 | -$1.31 | |||
2012-03-31 | 2012-05-30 | -$2.69 | |||
2011-12-31 | 2012-03-16 | $1.20 | -$4.80 | 125% | |
2011-09-30 | 2011-11-09 | -$1.20 | -$9.60 | 87.5% | |
2011-06-30 | 2011-08-09 | -$7.20 | -$7.20 | 0% | |
2011-03-31 | 2011-05-09 | -$6.00 | -$4.80 | -25% | |
2010-12-31 | 2011-03-16 | -$3.60 | -$3.60 | 0% | |
2010-09-30 | 2010-12-01 | -$3.35 | |||
2010-06-30 | 2010-09-01 | -$5.02 | |||
2010-03-31 | 2010-06-02 | -$2.61 | |||
2009-12-31 | 2010-03-31 | -$2.40 | -$3.60 | 33.33% | |
2009-09-30 | 2009-11-16 | -$2.40 | -$3.60 | 33.33% | |
2009-06-30 | 2009-09-02 | -$3.68 | |||
2009-03-31 | 2009-06-03 | -$3.18 | |||
2008-12-31 | 2008-12-31 | -$3.54 | |||
2008-09-30 | 2008-09-30 | -$2.60 | |||
2008-06-30 | 2008-06-30 | -$1.60 | |||
2008-03-31 | 2008-03-31 | -$2.83 | |||
2007-12-31 | 2007-12-31 | -$2.14 | |||
2007-09-30 | 2007-09-30 | -$2.48 | |||
2007-06-30 | 2007-06-30 | -$2.82 | |||
2007-03-31 | 2007-03-31 | -$2.83 | |||
2006-12-31 | 2006-12-31 | -$1.43 | |||
2006-09-30 | 2006-09-30 | -$4.08 | |||
2006-06-30 | 2006-06-30 | -$3.72 | |||
2006-03-31 | 2006-03-31 | -$6.92 | |||
2005-12-31 | 2005-12-31 | -$8.40 | |||
2005-09-30 | 2005-09-30 | -$3.20 | |||
2005-06-30 | 2005-06-30 | -$3.74 | |||
2005-03-31 | 2005-03-31 | -$240.01 | |||
2004-12-31 | 2004-12-31 | -$4,440.18 |
Rexahn Pharmaceuticals, Inc (REXN) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
Date |
---|
Research Development |
Income Before Tax |
Selling General Administrative |
Gross Profit |
Ebit |
Operating Income |
Income Tax Expense |
Total Revenue |
Cost of Revenue |
Total Other Income Expense Net |
Net Income From Continuing Operations |
Net Income Applicable to Common Shares |
Cash Flow:
Date |
---|
Investments |
Change to Liabilities |
Total Cash Flow from Investing Activities |
Net Borrowings |
Total Cash Flow from Financial Activities |
Change to Operating Activities |
Change in Cash |
Total Cash from Operating Activities |
Depreciation |
Other Cash Flow from Investing Activities |
Change to Inventory |
Change to Account Receivables |
Other Cash Flow from Financing Activities |
Change to Net Income |
Capital Expenditures |
Balance Sheet:
Date |
---|
Total Liabailities |
Total Stockholder Equity |
Other Current Liabilities |
Total Assets |
Common Stock |
Other Current Assets |
Retained Earnings |
Other Liabilities |
Other Assets |
Cash |
Total Current Liabilities |
Other Stockholder Equity |
Property, Plant & Equipment |
Total Current Assets |
Long Term Investments |
Net Tangible Assets |
Short Term Investments |
Long Term Debt |
Inventory |
Accounts Payable |
Rexahn Pharmaceuticals, Inc (REXN) Chart:
Rexahn Pharmaceuticals, Inc (REXN) News:
Below you will find a list of latest news for Rexahn Pharmaceuticals, Inc (REXN) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Rexahn Pharmaceuticals, Inc (REXN) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
---|
Rexahn Pharmaceuticals, Inc (REXN) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
Date | Form Type | Form Name | Link |
---|---|---|---|
2020-07-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036120015244/0001140361-20-015244-index.htm |
2018-07-13 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1228627/000000000018021523/0000000000-18-021523-index.htm |
2018-07-19 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1228627/000000000018022160/0000000000-18-022160-index.htm |
2019-07-12 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1228627/000000000019011080/0000000000-19-011080-index.htm |
2019-10-07 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1228627/000000000019014362/0000000000-19-014362-index.htm |
2019-02-05 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1228627/000091957419000760/0000919574-19-000760-index.htm |
2020-08-10 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1228627/000091957420004951/0000919574-20-004951-index.htm |
2018-10-26 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1228627/000110465918064080/0001104659-18-064080-index.htm |
2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1228627/000110465919008566/0001104659-19-008566-index.htm |
2018-06-18 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1228627/000114036118029005/0001140361-18-029005-index.htm |
2018-06-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036118030409/0001140361-18-030409-index.htm |
2018-06-28 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1228627/000114036118030411/0001140361-18-030411-index.htm |
2018-06-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1228627/000114036118030725/0001140361-18-030725-index.htm |
2018-06-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1228627/000114036118030728/0001140361-18-030728-index.htm |
2018-06-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1228627/000114036118030732/0001140361-18-030732-index.htm |
2018-06-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1228627/000114036118030736/0001140361-18-030736-index.htm |
2018-07-09 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1228627/000114036118031931/0001140361-18-031931-index.htm |
2018-07-18 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1228627/000114036118032806/0001140361-18-032806-index.htm |
2018-07-23 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1228627/000114036118033155/0001140361-18-033155-index.htm |
2018-08-03 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1228627/000114036118035394/0001140361-18-035394-index.htm |
2018-08-07 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1228627/000114036118035693/0001140361-18-035693-index.htm |
2018-08-07 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1228627/000114036118035696/0001140361-18-035696-index.htm |
2018-08-09 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1228627/000114036118036069/0001140361-18-036069-index.htm |
2018-08-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036118036732/0001140361-18-036732-index.htm |
2018-08-22 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1228627/000114036118036803/0001140361-18-036803-index.htm |
2018-08-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036118037339/0001140361-18-037339-index.htm |
2018-10-18 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1228627/000114036118040882/0001140361-18-040882-index.htm |
2018-10-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036118040906/0001140361-18-040906-index.htm |
2018-11-02 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1228627/000114036118042255/0001140361-18-042255-index.htm |
2018-11-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036118043281/0001140361-18-043281-index.htm |
2018-11-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1228627/000114036118043286/0001140361-18-043286-index.htm |
2018-12-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036118044418/0001140361-18-044418-index.htm |
2018-12-03 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1228627/000114036118044424/0001140361-18-044424-index.htm |
2018-12-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1228627/000114036118044426/0001140361-18-044426-index.htm |
2019-01-22 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1228627/000114036119001360/0001140361-19-001360-index.htm |
2019-01-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036119001362/0001140361-19-001362-index.htm |
2019-01-24 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1228627/000114036119001517/0001140361-19-001517-index.htm |
2019-01-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036119001600/0001140361-19-001600-index.htm |
2019-01-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1228627/000114036119001633/0001140361-19-001633-index.htm |
2019-01-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1228627/000114036119001635/0001140361-19-001635-index.htm |
2019-01-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1228627/000114036119001802/0001140361-19-001802-index.htm |
2019-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1228627/000114036119002080/0001140361-19-002080-index.htm |
2019-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1228627/000114036119002082/0001140361-19-002082-index.htm |
2019-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1228627/000114036119002419/0001140361-19-002419-index.htm |
2019-02-04 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1228627/000114036119002426/0001140361-19-002426-index.htm |
2019-02-14 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1228627/000114036119003255/0001140361-19-003255-index.htm |
2019-03-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036119004259/0001140361-19-004259-index.htm |
2019-03-01 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1228627/000114036119004269/0001140361-19-004269-index.htm |
2019-03-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1228627/000114036119004271/0001140361-19-004271-index.htm |
2019-03-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1228627/000114036119004274/0001140361-19-004274-index.htm |
2019-03-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1228627/000114036119004276/0001140361-19-004276-index.htm |
2019-03-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036119004489/0001140361-19-004489-index.htm |
2019-03-07 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1228627/000114036119004539/0001140361-19-004539-index.htm |
2019-03-11 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1228627/000114036119004632/0001140361-19-004632-index.htm |
2019-03-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036119004634/0001140361-19-004634-index.htm |
2019-04-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036119006977/0001140361-19-006977-index.htm |
2019-04-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036119007130/0001140361-19-007130-index.htm |
2019-04-29 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1228627/000114036119007856/0001140361-19-007856-index.htm |
2019-05-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1228627/000114036119008945/0001140361-19-008945-index.htm |
2019-05-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036119009949/0001140361-19-009949-index.htm |
2019-06-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036119010648/0001140361-19-010648-index.htm |
2019-06-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1228627/000114036119010668/0001140361-19-010668-index.htm |
2019-06-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1228627/000114036119010669/0001140361-19-010669-index.htm |
2019-06-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1228627/000114036119010671/0001140361-19-010671-index.htm |
2019-06-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1228627/000114036119010673/0001140361-19-010673-index.htm |
2019-06-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1228627/000114036119010676/0001140361-19-010676-index.htm |
2019-06-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1228627/000114036119010678/0001140361-19-010678-index.htm |
2019-06-07 | 25 | Notification of the removal from listing and registration of matured, redeemed or retired securities | https://www.sec.gov/Archives/edgar/data/1228627/000114036119010682/0001140361-19-010682-index.htm |
2019-06-07 | 8-A12B | Registration of securities [Section 12(b)] | https://www.sec.gov/Archives/edgar/data/1228627/000114036119010684/0001140361-19-010684-index.htm |
2019-07-26 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1228627/000114036119013497/0001140361-19-013497-index.htm |
2019-08-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036119014411/0001140361-19-014411-index.htm |
2019-08-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1228627/000114036119014413/0001140361-19-014413-index.htm |
2019-08-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036119015750/0001140361-19-015750-index.htm |
2019-08-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036119015801/0001140361-19-015801-index.htm |
2019-11-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1228627/000114036119019932/0001140361-19-019932-index.htm |
2020-02-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036120002721/0001140361-20-002721-index.htm |
2020-02-21 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1228627/000114036120003785/0001140361-20-003785-index.htm |
2020-03-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036120005875/0001140361-20-005875-index.htm |
2020-04-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036120008410/0001140361-20-008410-index.htm |
2020-04-29 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1228627/000114036120010048/0001140361-20-010048-index.htm |
2020-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1228627/000114036120010906/0001140361-20-010906-index.htm |
2020-06-18 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1228627/000114036120014136/0001140361-20-014136-index.htm |
2020-06-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036120014267/0001140361-20-014267-index.htm |
2020-06-19 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1228627/000114036120014268/0001140361-20-014268-index.htm |
2020-07-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036120015244/0001140361-20-015244-index.htm |
2020-07-01 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1228627/000114036120015245/0001140361-20-015245-index.htm |
2020-07-06 | S-4 | Registration of securities, business combinations | https://www.sec.gov/Archives/edgar/data/1228627/000114036120015421/0001140361-20-015421-index.htm |
2020-08-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036120017238/0001140361-20-017238-index.htm |
2020-08-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1228627/000114036120018406/0001140361-20-018406-index.htm |
2020-08-27 | S-4/A | Registration of securities, business combinations | https://www.sec.gov/Archives/edgar/data/1228627/000114036120019177/0001140361-20-019177-index.htm |
2020-09-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036120019615/0001140361-20-019615-index.htm |
2020-09-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036120020176/0001140361-20-020176-index.htm |
2020-09-16 | S-4/A | Registration of securities, business combinations | https://www.sec.gov/Archives/edgar/data/1228627/000114036120020569/0001140361-20-020569-index.htm |
2020-09-30 | S-4/A | Registration of securities, business combinations | https://www.sec.gov/Archives/edgar/data/1228627/000114036120021938/0001140361-20-021938-index.htm |
2020-10-02 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1228627/000114036120022250/0001140361-20-022250-index.htm |
2020-10-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036120022798/0001140361-20-022798-index.htm |
2020-10-09 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1228627/000114036120022799/0001140361-20-022799-index.htm |
2020-10-16 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1228627/000114036120023152/0001140361-20-023152-index.htm |
2020-10-20 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1228627/000114036120023372/0001140361-20-023372-index.htm |
2020-10-29 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1228627/000114036120024042/0001140361-20-024042-index.htm |
2020-11-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036120024376/0001140361-20-024376-index.htm |
2020-11-03 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1228627/000114036120024377/0001140361-20-024377-index.htm |
2020-11-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000114036120024749/0001140361-20-024749-index.htm |
2018-10-29 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1228627/000119312518310598/0001193125-18-310598-index.htm |
2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1228627/000119312519040135/0001193125-19-040135-index.htm |
2019-06-10 | CERT | Certification | https://www.sec.gov/Archives/edgar/data/1228627/000135445719000304/0001354457-19-000304-index.htm |
2019-03-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1228627/000156761919007648/0001567619-19-007648-index.htm |
2020-10-02 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1228627/999999999520002720/9999999995-20-002720-index.htm |
2018-12-17 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1228627/999999999718009562/9999999997-18-009562-index.htm |
2019-08-15 | SEC STAFF | SEC Staff Letter: REDACTED EXHIBIT | https://www.sec.gov/Archives/edgar/data/1228627/999999999719006516/9999999997-19-006516-index.htm |
2019-10-07 | SEC STAFF | SEC Staff Letter: REDACTED EXHIBIT | https://www.sec.gov/Archives/edgar/data/1228627/999999999719007242/9999999997-19-007242-index.htm |
Rexahn Pharmaceuticals, Inc (REXN) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Rexahn Pharmaceuticals, Inc (REXN). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 22%Institutional Ownership: 833%
Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
---|---|---|---|---|---|---|---|---|
2019-01-31 | Charles Beever | Director | Buy | 10,000.00 | 0.64 | 6,380.00 | 11,000.00 | https://www.sec.gov/Archives/edgar/data/1228627/000114036119002419/0001140361-19-002419-index.htm |
2019-01-29 | Ben Gil Price | Director | Buy | 15,000.00 | 0.61 | 9,141.00 | 15,000.00 | https://www.sec.gov/Archives/edgar/data/1228627/000114036119002082/0001140361-19-002082-index.htm |
2019-01-30 | Lisa Nolan | Chief Business Officer | Buy | 20,000.00 | 0.65 | 12,960.00 | 21,625.00 | https://www.sec.gov/Archives/edgar/data/1228627/000114036119002080/0001140361-19-002080-index.htm |
2019-02-28 | Lisa Nolan | Chief Business Officer | Buy | 1,625.00 | 23,250.00 | https://www.sec.gov/Archives/edgar/data/1228627/000114036119004276/0001140361-19-004276-index.htm | ||
2019-02-28 | Ely Benaim | Chief Medical Officer | Buy | 2,375.00 | 4,750.00 | https://www.sec.gov/Archives/edgar/data/1228627/000114036119004274/0001140361-19-004274-index.htm | ||
2019-01-29 | Douglas J Swirsky | President and CEO | Buy | 50,000.00 | 0.63 | 31,720.00 | 50,000.00 | https://www.sec.gov/Archives/edgar/data/1228627/000114036119001802/0001140361-19-001802-index.htm |